The Incidence of Transfusion-Related Acute Lung Injury (TRALI) Following Blood Product Transfusion in Patients Undergoing Elective Orthopedic-Oncology Procedures
Sponsor study identifier
observational
550
1 country
1
Study Start
August 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Currently Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality in the United States, and one of major post-transfusion complications. TRALI is defined as new ALI occurring within 6 hours from the onset of transfusion. It is manifested by acute dyspnea, hypoxemia and bilateral infiltrates in chest radiograph. TRALI may be caused by any blood product and is not dose-dependent. Associated risk factors include prolonged storage of blood products and underlying conditions such as severe IHD hematologic malignancies or active infections. Since TRALI has only recently been defined as a clinical entity, and its prevalence has been largely underestimated - the epidemiology of TRALI is not well established. Therefore the objective of this work is to study the incidence of TRALI in a patient population that receive blood products frequently, namely orthopedic-oncologic.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 4, 2009
Actual (reported)June 5, 2009
Actual (reported)August 2009
Date type not reportedThis date has not been verified as actual or estimated.
August 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The incidence of TRALI in patients undergoing orthopedic-oncology procedures, following blood product transfusion
2 years
The correlation between the incidence of TRALI and the age of blood product
2 years
Patients aged \>18 years old, with ASA I-III, undergoing elective orthopedic-oncology procedures in the Sourasky Medical Center, and receiving blood products pre-, intra-, or post-operatively.
Tel Aviv Sourasky medical center
Tel Aviv, 64239, Israel
blood from arterial line to test for PaO2
Idit Matot, MD
Tel-Aviv Sourasky Medical Center
First Submitted
June 4, 2009
First Posted
June 5, 2009
Study Start
August 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2011
Estimated (date passed)Fluid Management in the Post-Anesthetic Care Unit (PACU) at Sourasky Medical Center
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 5, 2009
Record last verified: 2009-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: